CHEMOTHERAPY PREPARATION AND STABILITY CHART

April 6, 2018 | Author: Anonymous | Category: Documents
Share
Report this link


Description

1. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Aldesleukin 22 million IU 1.2 mL SWI1,2 18 million IU/mL 48 h F1 50 mL D5W1 48 h F1 - cytotoxic3 (1.3 mg) (1.1 mg/mL)1,2 - do not use in-line (Novartis) direct diluent against 30 – 70 mcg/mL1 filter1,2 (F)(PFL) side of vial during - avoid no preservative1 reconstitution1 < 30 mcg/mL: dilute in bacteriostatic water D5W containing for injection or NS do not shake1 human albumin 0.1%2 due to increased aggregation1 Alemtuzumab - cytotoxic7 5 6 30 mg/mL N/A filter NOT required discard unused SC syringe discard at the end of - do not shake8 (Genzyme previously portion5 the day F or RT Bayer)4 30 mg/mL5 (F)(PFL) do not shake no preservative5 100 mL NS or D5W5 8 h F or RT5 **(PFL)8 Alemtuzumab 30 mg/3 mL N/A use 5 micron filter discard unused SC syringe6 discard at the end of - cytotoxic7 (Schering/Ilex) to withdraw drug portion9 the day F or RT8 - do not shake8 (F)(PFL) from ampoule8 do not shake no preservative9 10 mg/mL9 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 1/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 2. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) 100 mL NS or D5W9 8 h F or RT8 **(PFL)8 Amifostine 500 mg 9.7 mL NS only10 50 mg/mL10 24 h F, 5 h RT10 25–50 mL*NS only10 5–40 mg/mL: - noncytotoxic10 (MedImmune) 24 h F,10 5 h RT - discard cloudy (RT) solution11 no preservative10 Amsacrine 75 mg/1.5 mL glass syringes 5 mg/mL12 24 h RT12 500 mL D5W12 7 d F, 48 h RT12,13,14 - cytotoxic15 (Erfa Canada) preferred during (RT) reconstitution; PFL12 (plastic or glass no preservative12 max. time in plastic container)12 syringe12: 15 min 13.5 mL supplied diluent (L-lactic acid)1 transfer 1.5mL from ampoule into the diluent vial12 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 2/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 3. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Asparaginase16 (asparaginase E. coli) do not shake; roll to 2500 units/mL16 48 h F, RT16 syringe16 14 d F20, 16 - cytotoxic3 10,000 units reconstitute18,11 (Orphan 4 mL SWI19 Pharmaceutical Intradermal test11: International)  Reconstitute with (F) 5 mL SWI to give no preservative17 2000 units/mL  Transfer 0.1 mL to 10 mL vial (or 12 mL syringe)  Add 9.9 mL SWI roll to dissolve to give 20 units/mL  2 unit test dose = 0.1 mL (Note: the rest of the reconstituted vial has a concentration of 2000 units/mL)11 50 mL*NS or D5W20,13 14 d F,20,13 2 d RT20,21 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 3/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 4. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Erwinia asparaginase (asparaginase Erwinia do not shake; roll to 10000-5000 15 min in original glass or 8 h in a glass or - cytotoxic3 chrysanthemi) reconstitute22 units/mL container; 8 h in a polypropylene polypropylene 10,000 units glass or syringe22 syringe22 (Orphan 1-2 mL NS22 polypropylene Pharmaceuticals syringe22 International) (F) no preservative22 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 4/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 5. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) PEG-asparaginase (pegasparagase) N/A 750 units/mL23 discard unused IM: maximum volume syringe: 4 h23,24 - cytotoxic3 (pegylated portion23 2 mL; if >2 mL use - discard cloudy asparaginase E. coli) multiple sites23 solution23 750 units/mL - do not shake23 (Enzon) - do not use if (F) stored out of no preservative23 refrigerator for > 48 h23 - do not use if previously frozen23 IV: 100 mL NS or bag: 4 h23,24 D5W23 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 5/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 6. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Azacitidine 100 mg 4 mL SWI25 25 mg/mL25 8 h F, SC syringe25 45 min RT25 - cytotoxic3 (Celgene) 45 min RT25 (RT) shake vigorously25 prepare immediately - discard if contains no preservative25 before use and use large particles25 within 45 min, or discard. - re-suspend syringe contents before injection by vigorously rolling syringe between palms25 BCG 81 mg do not shake; roll to 10.5 ± 8.7×108 2 h F, RT26 50 mL NS26 2 h F or RT after - cytotoxic7 (Sanofi Pasteur) reconstitute26 CFU/vial reconstitution26 (F)(PFL) (Connaught preservative26 3 mL supplied strain)26 **(PFL)26 diluent26 record time of reconstitution BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 6/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 7. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) BCG (Tice substrain) 1 mL preservative 1 to 8×108 2 h F (PFL)27 transfer from vial to 2 h F27 - cytotoxic3 50 mg = 1 to 8 x 108 free NS for CFU/vial27 60 mL syringe, rinse - overfill unknown CFU injection27 vial with another 1 mL - protect from (Hospira/Organon) NS. Add rinse to light27 (F)(PFL) use reconstitution same 60 mL syringe. - do not filter27 no preservative27 device provided qs to 50 mL with NS27 allow to stand for a few minutes, then gently swirl to suspend27 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 7/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 8. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Bendamustine 25 mg single-use vial 25 mg vial: add 5 5 mg/mL28 30 minutes28 500 mL NS28 24 h F, 3 h RT28 - cytotoxic3 100 mg single-use vial mL SWI (Cephalon) 100 mg vial: add 20 0.2-0.6 mg/mL28 (RT)(PFL) mL SWI28 no preservative28 Shake well to yield a clear, colourless to a pale yellow solution. Expected to completely dissolve within 5 minutes28 Bevacizumab 100 mg/4 mL N/A 25 mg/mL29 discard unused 1.4-16.5 mg/mL30 48 h F, RT21,29,30 - cytotoxic7 400 mg/16 mL portion29 - do not shake29 (Roche) 100-250 mL NS (F)(PFL) only29,30 do not shake no preservative29 Bleomycin 15 IU 6 mL*NS31 2.5 IU/mL 48 h F31 50 mL*NS31 24 h RT31 - cytotoxic7 (NB: dose in units only) - no overfill32 (Bristol) (F) no preservative31 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 8/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 9. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Bleomycin 15 IU 6 mL*NS or SWI33 2.5 IU/mL33 48 h F, 24 h RT33 50 mL *NS, SWI33 24 h RT34 - cytotoxic7 (NB: dose in units only) - no overfill35 (Hospira) (F)(PFL) no preservative33 Bortezomib 3.5 mg 3.5 mL NS36 1 mg/mL36 2d RT13,37 syringe36 8 h RT38 - cytotoxic7 (Ortho Biotech formally Millennium) (RT)(PFL) no preservative36 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 9/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 10. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Busulfan 60 mg/10 mL N/A use 5-micron nylon discard unused NS or D5W (dilute in complete - cytotoxic7 (Orphan Medical) filter provided with portion39 volume 10 times the administration within (F) ampoule to busulfan volume to ~ 12 h F: NS39 no preservative39 withdraw drug39 0.5 mg/mL)39 8 h RT: NS, D5W 6 mg/mL39 Carboplatin 50 mg/5 mL N/A 10 mg/mL40 discard unused 0.3-10 mg/mL41 24 h RT,42 48 h F40 - cytotoxic7 150 mg/15 mL portion40 - do NOT use 450 mg/45 mL NS, D5W11,40 aluminum- (Hospira) containing needle, (RT)(PFL) do NOT use syringe or tubing41 no preservative40 aluminum-containing needle or syringe41 Carboplatin 50 mg/5 mL N/A 10 mg/mL43 discard unused 0.5-10 mg/mL44 8 h RT43 - cytotoxic7 150 mg/15 mL portion RT43 - do NOT use 450 mg/45 mL NS, D5W11,43,45 aluminum- (Novopharm) containing needle, (RT)(PFL) do NOT use syringe or tubing43 no preservative43 aluminum-containing needle or syringe43 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 10/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 11. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Carmustine 100 mg 3 mL diluent 3.3 mg/mL in 10% 24 h F, 8 h RT46 glass46 or polyolefin 24 h F: in glass,46 or - cytotoxic7 (Bristol Labs) (supplied)46 ethanol46 container11 polyolefin container11 - do not use if (F) product has oily no preservative46 diluent to reach RT, 500 mL NS or D5W46 use within 4 h of droplets46 then dissolve drug reconstitution RT46 with 3 mL diluent; add 27 mL SWI46 record time of reconstitution Cetuximab 100 mg/50 mL N/A 2 mg/mL47 discard unused syringe47 12 h F, 8 h RT47 - cytotoxic3 200 mg/100 mL portion after 12 h - administer with a (ImClone/BMS) F, 8 h RT47 0.2 or 0.22 micron (F) low protein binding do not dilute sterile evacuated 12 h F, 8 h RT47 in-line filter47 do not shake container or bag e.g. - normal saline no preservative47 polyolefin, may be used to polyethylene, flush the line47 ethylene vinyl - solution may acetate, DEHP contain white plasticized PVC, PVC particulates which bag, or glass47 do not affect product quality47 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 11/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 12. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Cisplatin 10 mg/10 mL N/A 1 mg/mL48 48 h RT49 < 60 mg: 100 mL NS* 48 h RT49 - cytotoxic7 50 mg/50 mL > 60 mg: 250 mL NS* - do NOT use 100 mg/100mL aluminum- (Hospira) 500 or 1000 mL *NS, containing needle, (RT)(PFL) D5-NS, D5-1/2S; D5- syringe or tubing48 no preservative48 NS with mannitol; D5- 1/2S with mannitol48,50; D5W- 1/3S with mannitol48 do NOT use aluminum-containing needle or syringe48 Cladribine 10 mg/10 mL N/A 1 mg/mL51 discard unused SC syringe52 48h F, end of day - cytotoxic7 (Janssen-Ortho) portion51 RT13,51,53,54 - shake vigorously (F)(PFL) cassette51 to dissolve any no preservative51 precipitates from refrigeration11 - bacteriostatic NS contains benzyl alcohol51 500 mL NS only51 24 h RT51 Do NOT use D5W51 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 12/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 13. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) qs to 100 mL with at least 7 days51 bacteriostatic NS only via SIMS DELTEC INC. MEDICATION CASSETTES®51; filter drug and diluent through 0.22u filter as each solution is being introduced into the medication Clodronate 300 mg/10 mL N/A 30 mg/mL discard unused 500 mL NS or D5W55 12 h RT55 - noncytotoxic (Oryx) portion55 (RT) no preservative55 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 13/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 14. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Cyclophosphamide 200 mg NS56 20 mg/mL56 72 h F,56,57 24 h < 1 g: 100 mL NS* 72 h F,56,57 24 h RT56 - cytotoxic7 500 mg RT56 > 1 g: 250 mL NS* 1000 mg 200 mg: 10 mL high dose in BMT: 2000 mg 500 mg: 25 mL may need 500 NS* (Baxter) 1000 mg: 50 mL (RT)(PFL) 2000 mg: 100 mL56 NS, D5W, D5NS56 no preservative56 Cyclosporine N/A 50 mg/mL58 discard unused NS, D5W58 dilute immediately prior - cytotoxic3 50 mg/1 mL portion58 to use58 250 mg/5 mL dilute to concentration (Novartis) between 1:20 and - polyoxyethylated (RT)(PFL) 1:10058 castor oil/ethanol no preservative58 vehicle58 - do NOT refrigerate or freeze58 - use non-PVC bag and tubing59 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 14/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 15. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Cytarabine 100 mg/1 mL N/A 100 mg/mL60 24 h RT60 100 mL*NS, Water for 72 h F, 24 h RT from - cytotoxic7 1000 mg/10mL Injection, D5W, initial vial puncture60 - do not use for IT 2000 mg/20mL record time of Lactated Ringer’s60 injection (Hospira) puncture (RT)(PFL) no preservative60 Cytarabine IT injection60 N/A 100 mg/mL60 24 h RT60 diluents containing use within 4 h of initial - cytotoxic7 100 mg/1 mL preservatives should vial puncture11,13 - auxiliary label62: 1000 mg/10mL record time of NOT be used for “IT” 2000 mg/20mL puncture intrathecal - label to include (Hospira) administration60 route in full (i.e., (RT)(PFL) INTRATHECAL no preservative60 qs to 6 mL with injection) attached preservative free NS61 to both syringe and outer ziplock bag62 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 15/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 16. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Cytarabine SC injection: 100 mg: 5 mL BWI63 100 mg: 48 h RT63,64 syringe 14 d F, 48 h RT64 - cytotoxic7 100 mg 20 mg/mL63 - for high dose (Pfizer) use, do not use (RT)(PFL) diluent containing no preservative63 benzyl alcohol65 - do not use for IT injection Dacarbazine 100 mg 100 mg: 9.9 mL 10 mg/mL66 72 h F, 8 h RT66 250-500 mL*NS or 24 h F, 8 h RT66 - cytotoxic7 200 mg SWI66 D5W - protect container (Abraxis) 200 mg: 19.7 mL **(PFL)11,66 from light during (F)(PFL) SWI66 see Special storage and no preservative66 Precautions/Notes administration67 Column - overfill unknown Dacarbazine 200 mg 200 mg: 19.7 mL 10 mg/mL68 48 h F, 8 h RT68 0.19–3.0 mg/mL13,68 24 h F68 - cytotoxic7 600 mg SWI68 - protect container (Hospira) 600 mg: 59.1 mL (PFL)69 250-500 mL*NS or **(PFL)67 from light during (F)(PFL) SWI68 D5W see Special storage and no preservative68 Precautions/Notes administration67 Column - no overfill69,35 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 16/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 17. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Dactinomycin 0.5 mg 1.1 mL 0.5 mg/mL71 24 h F, RT72 syringe71,73 24 h F, RT 74 - cytotoxic3 (Ovation)70 SWI(preservative (500 mcg/mL) - do not filter71,73 (RT)(PFL) free)71 . no preservative71 Do NOT use SWI with preservative (may form precipitate)71 BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Daunorubicin 20 mg 4 mL SWI75 5 mg/mL75,78 48 h F, 24 h RT77 100-250 mL in 24 h RT, 48 h F75 - cytotoxic3 (Erfa Canada Inc.)75 isotonic solution e.g., (RT)(PFL)76 NS75 no preservative77 no data for D5W77 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 17/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 18. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Daunorubicin 20 mg 4 mL SWI79 5 mg/mL79 24 h RT, 48 h F79 100-250 mL 48 h F, 24 h RT79 - cytotoxic7 (Novopharm) NS or D5W11 (RT)(PFL) (PFL)79 **(PFL)79 no preservative79 Dexrazoxane 250 mg supplied diluent80: 10 mg/mL80 6 h F80 empty viaflex bag80 6 h RT81 - cytotoxic82 500 mg 250 mg: 25 mL (Pfizer) 500 mg: 50 mL (RT) no preservative80 Docetaxel 20 mg/0.5 mL supplied diluent : 10 mg/mL83 48 h F, RT13,85 0.3–0.74 mg/mL complete - cytotoxic7 80 mg/2 mL - if vials were administration within - non-PVC bag and (Sanofi-Aventis) refrigerated, allow to (e.g., 250 mL NS or 4 h F,83 48 h RT86,87 tubing only83 (F, RT) (PFL) warm for 5 min at D5W)83 no preservative83 RT. Withdraw entire contents of the diluent and inject the entire contents of the syringe into the corresponding concentrate vial. Mix by repeated inversions for 45 sec DO NOT SHAKE Let sit for 5 minutes83,84 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 18/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 19. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Doxorubicin 10 mg NS, SWI, D5W88 2 mg/mL88 48 h F, 24 h syringe88 48 h F, 24 h RT13,89 - cytotoxic7 50 mg (NS reconstitution RT13,88 150 mg takes longer) (Hospira) 10 mg: 5 mL (RT)(PFL) 50 mg: 25 mL no preservative88 150 mg: 75 mL 0.2–2 mg/mL90 48 h F, 24 h RT13,90 100 mL*NS88 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 19/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 20. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Doxorubicin 10 mg/5 mL N/A 2 mg/mL 8 h91 syringe91 48 h F, 24 h RT91 - cytotoxic7 20 mg/10 mL from initial vial 50 mg/25 mL record time of puncture 200 mg/100 mL puncture (Novopharm) (F)(PFL) no preservative91 Doxorubicin 10 mg/5 mL N/A 2 mg/mL92 discard unused syringe92 48 h F, 24 h RT92 - cytotoxic3 50 mg/25 mL portion92,74 200 mg/100 mL (Pfizer) (F) no preservative92 Doxorubicin Pegylated Liposomal N/A 2 mg/mL93 discard unused < 90 mg: 250 mL 24 h F93 - cytotoxic7 20 mg/10 mL portion93 D5W only93 - do not filter93 50 mg/25 mL (Schering) ≥ 90 mg: 500mL D5W (F) only no preservative93 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 20/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 21. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Epirubicin 10 mg/5 mL N/A 2 mg/mL94 8 h94 syringe94 48 h F, 24 h RT from - cytotoxic7 50 mg/25 mL initial vial puncture94 200 mg/100 mL record time of (Pfizer) puncture (F)(PFL) no preservative94 100 mL*NS or D5W11 2 d F, RT: NS or D5W49 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 21/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 22. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Etoposide 100 mg/5 mL N/A 20 mg/mL95 14 d RT11,13,96,97,98 0.2– 0.4 mg/mL95 0.2 mg/mL: - cytotoxic7 500 mg/25 mL 48 h RT13,95 - use non-PVC bag 1000 mg/50 mL 500 mL*NS or D5W95 0.4 mg/mL: and tubing only (BMS) 24 h RT95 (RT) preservative95 Etoposide 0.2-0.3 mg/mL: 100 mg/5 mL N/A 20 mg/mL99 discard unused NS 7 d F,100 2 d RT87,100 - cytotoxic7 200 mg/10 mL portion99 0.4-0.5 mg/mL: - use non-PVC bag 500 mg/25 mL Stabilty is 1 d F,100 1 d RT100 and tubing only 1000 mg/50 mL concentration 0.6-9.0mg/mL: (Novopharm) dependent generally unstable100 (RT)(PFL) 9.5 mg/mL: no preservative99 2 d F,100 1d RT100 10-12 mg/mL: 7 d F,100 2 d RT87,100 D5W99 4 h RT99,101 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 22/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 23. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Fludarabine 50 mg 2 mL SWI102 25 mg/mL102 48 h F or RT13,49 dilute to maximum of 48 h F, RT13,49 - cytotoxic7 (Berlex) 1 mg/mL102,103 (F) no preservative102 100 mL*NS or D5W102 Fludarabine 50 mg N/A 25 mg/mL104 discard unused dilute to maximum of 48 h F, 24 h RT104 - cytotoxic7 (Novopharm) portion104 1 mg/mL104 (F) no preservative104 100 mL*NS or D5W BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 23/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 24. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Fluorouracil 5000 mg/100 mL N/A 50 mg/mL105 8 h RT105,106 syringe13 48 h RT13,21,106 - cytotoxic7 (Hospira) (RT)(PFL) no preservative105 2-10 mg/mL in 24 h RT105,106 D5W105,106 50-1000 mL*D5W CIVI: ambulatory complete within pump106 8 d11,13,107 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 24/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 25. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Gemcitabine 200 mg 200 mg: 5 mL NS 38 mg/mL108 48 h RT108,109 syringe108 48 h RT,13,108,109 - cytotoxic7 1000 m g 1000 mg: 25 mL (Eli-Lilly) NS108 (RT) no preservative108 0.1–10 mg/mL 48 h F, RT13,108,109 NS108,109 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 25/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 26. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Gemcitabine 200 mg 200 mg vial: 5 mL 38 mg/mL110 48 RT110,112,74 syringe110 24 h RT110,112 - cytotoxic7 1000 mg NS 2000 mg 1000 mg vial: 25 mL (Hospira) NS RT110 2000 mg vial: 50 mL no preservative111 NS110 26 mg/mL-0.1 mg/mL 48 h RT112,74 NS110,112 Gemcitabine 200 mg 200 mg vial: 5mL 38 mg/mL114 24 h RT114 38 mg/mL – 0.1 24 RT114 - cytotoxic7 1000 mg NS mg/mL NS114 (Novopharm) 1000 mg vial: 25 mL RT NS114 no preservative113 Gemcitabine 200 mg 200 mg vial: 5 mL 38 mg/mL115 48 h RT115,116 syringe115 48 h RT115,117,116 - cytotoxic7 1000 mg NS (Sandoz Standard) 1000 mg vial: 25 mL RT NS115 no preservative115 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 26/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 27. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) 38 mg/mL-0.1 mg/mL 48 h RT13,119 NS or D5W115,118 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 27/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 28. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Idarubicin 5 mg vial under negative 1 mg/mL120 48 h F,120 24 h RT syringe 48 h F,13, 120 24 h RT13 - cytotoxic7 10 mg pressure120 (PFL)120 (PFL)120 (Pfizer) (RT)(PFL) 5 mg: 5 mL SWI no preservative120 10 mg: 10 mL SWI120 Idarubicin 5 mg/5 mL N/A 1 mg/mL120 same as syringe Discard 48 h F,13,120 24 - cytotoxic7 10 mg/10 mL reconstituted h RT13 20 mg/20 mL solution121 (PFL)120 (Pfizer) (F)(PFL) no preservative120 Ifosfamide 1000 m g 1000 mg: 20 mL 50 mg/mL122 48 h F13,122 0.6–20 mg/mL122 72 h F122 - cytotoxic7 3000 mg SWI122 24 h F, RT when mixed (Baxter) 3000 mg: 60 mL 500–1000 mL*NS, with mesna11 (RT) 11 SWI D5W, D5-NS, no preservative122 D5-1/2NS, Lactated D5W or Lactated shake well Ringer’s11,122 Ringer’s when mixed Interferon Alfa -2b 18 million IU/3 mL N/A 6 million IU/mL123 48 h F13,123 syringe123 2 d F13,124 - cytotoxic7 (Schering) (F)(or up to 7 days at RT before use) no preservative123 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 28/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 29. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) ≥ 0.3 million IU/mL123 24 h F, RT124 50 mL NS123 Interferon Alfa -2b 25 million IU/2.5 mL N/A 10 million IU/mL123 48 h F13,123 syringe123 2 d F13,124 - cytotoxic7 (Schering) (F)(or up to 7 days at RT before use) no preservative123 ≥ 0.3 million IU/mL123 24 h F, RT124 50 mL NS123 Interferon Alfa -2b 10 million IU 1 mL supplied 10 million IU/mL123 24 h F123 syringe123 24 h F, RT124 - cytotoxic7 (Schering) diluent (SWI) 123 (F) no preservative123 do not shake; roll to reconstitute123 > 0.1 million IU/mL124 48 h RT11,13 100 mL NS125 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 29/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 30. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) 1 mL BWI123 48 h F, RT13,123 syringe125 14 d F, 48 h RT13,125 do not shake; roll to reconstitute123 100 mL NS125 48 h RT11,13 Interferon Alfa -2b 18 million IU 1 mL supplied 18 million IU/mL123 24 h F123 syringe123 24 h F, RT124 - cytotoxic7 (Schering) diluent123 (F) no preservative123 do not shake; roll to reconstitute123 > 0.1 million IU/mL126 48 h RT11,13 100 mL NS125 1 mL BWI123 48 h F, RT13 syringe123 14 d F13,125 do not shake; roll to reconstitute123 100 mL NS125 48 h RT11,13 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 30/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 31. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Irinotecan 40 mg/2 mL N/A 20 mg/mL127 2 days RT13,128,129 0.12– 2.8 mg/mL127 24 h RT: D5W, NS127 - cytotoxic7 100 mg/5 mL - do NOT 500 mg/25 mL 500 mL11 D5W 48 h F: D5W refrigerate if in (Hospira) (preferred), NS127 (PFL)127 NS130 (RT)(PFL) no preservative127 Irinotecan 40 mg/2 mL N/A 20 mg/mL130 discard unused 0.12– 2.8 mg/mL130 24 h RT: D5W, NS130 - cytotoxic7 100 mg/5 mL portion130 - do NOT (Pfizer) 500 mL11 D5W 48 h F: D5W refrigerate if in (RT)(PFL) (preferred), NS130 (PFL)130 NS130 no preservative130 Irinotecan 40 mg/2 mL N/A 20 mg/mL131 discard unused 0.12-2.8 mg/mL131 24 h RT: D5W NS131 - cytotoxic3 100 mg/5 mL portion131,74 48 h F: D5W131 (Sandoz) D5W (recommended) (RT)(PFL) NS131 (PFL)131 no preservative131 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 31/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 32. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Ixabepilone 15 mg 8 mL supplied 2 mg/mL 1 h RT132 0.2 – 0.6 mg/mL in 6 h RT132 - cytotoxic3 (contains 16 mg) diluent Lactated Ringer’s - use 0.2-1.2 45 mg Injection USP (use micron in-line (contains 47 mg) 23.5 mL supplied 2 mg/mL non-PVC infusion filter132 (BMS) diluent container)132 - use non-PVC (F)(PFL) (i.e., DEHP-free) no preservative132 administration set132 Leucovorin 50 mg/5 mL N/A 10 mg/mL133 5 mL vial: discard syringe134 7 d F134 - noncytotoxic 500 mg/50 mL unused portion133 48 h RT87,134 (Hospira) (F)(PFL) 50 mL vial: 8 h no preservative133 0.05-10 mg/mL133 24 h RT133: NS, D5W, Lactated Ringer’s, Ringer’s 50-250 mL* NS, 8 h RT133: D10W, D5- D5W, Lactated NS Ringer’s, Ringer’s, D10W, D5-NS BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 32/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 33. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Leucovorin 50 mg/5 mL N/A135 10 mg/mL135 5 mL vial: discard syringe 8 h135,13 - noncytotoxic 500 mg/50 mL unused portion135 (Novopharm) (F)(PFL)135 50 mL vial: discard unused portion135 0.060-1.0 mg/mL135 24 h RT NS, Lactated Ringer’s, Ringer’s135 50-250 mL* NS, 12 h RT D5W, D5W, Lactated D10W135 Ringer’s, Ringer’s, D10W, D10NS135 6 h RT D5NS135 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 33/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 34. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Mechlorethamine 10 mg do NOT use if 1 mg/mL136 use within 4 h of syringe136 complete - cytotoxic7 (Ovation discoloured or water reconstitution administration Pharmaceuticals/Merck) droplets form in vial RT11,13 4 h of reconstitution no preservative136 before RT11,13,136 reconstitution136 10 mL SWI or NS136 record time of reconstitution 100 mL NS49,136 complete administration within 4 h of reconstitution RT13,49,136 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 34/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 35. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Medroxyprogesterone 250 mg/5 mL N/A 50 mg/mL18 use within 4 h of syringe: IM only18 use within 4 h of initial - cytotoxic7 (Pfizer) initial vial puncture11,137 - auxiliary label: (RT) record time of puncture11,137 shake before use18 preservative18 puncture Medroxyprogesterone Depo N/A 150 mg/mL18 use within 4 h of syringe: IM only18 use within 4 h of initial - cytotoxic7 150 mg/1mL initial puncture11,137 - auxiliary label: (Pfizer) record time of puncture11,137 shake before use18 (RT) puncture preservative18 Melphalan 50 mg 10mL supplied 5 mg/mL138 2 h RT138 0.1– 0.45 mg/mL in complete - cytotoxic7 (GSK) diluent138 NS only138 administration within (RT)(PFL) do NOT 60 min from time of no preservative138 immediately after refrigerate (e.g., > 45 mg and < initial reconstitution at adding diluent, 110 mg in 250 mL RT11 shake vigorously138 NS)* record time of reconstitution BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 35/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 36. Mesna 1000 mg/10mL N/A 100 mg/mL139 14 d F, RT13,139 > 1mg/mL139 48 h F, 24 h RT139 - noncytotoxic (PPC) (RT) NS or D5W preservative139 Methotrexate 50 mg/2mL N/A 25 mg/mL140 50mg: discard syringe 2 d F, RT11,141,142 - cytotoxic7 500 mg/20mL unused portion140 - for high-dose 1 g/40mL regimens (e.g., 1-8 5 g/200mL 500mg, 1 g, 5 g: g/m2 as a single (Hospira) 8 h F, RT140 dose)143 use (RT)(PFL) preservative-free no preservative140 methotrexate11 - do not use for IT injection 0.4–2 mg/mL140 24 h RT140 100 mL* NS, D5W high dose (e.g., 1-8 g/m2 as a single dose)143,144-146: 500– 1000 mL* BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 36/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 37. Methotrexate IT Injection140: N/A 25 mg/mL140 discard unused qs to 6 mL with use within 4 h of initial - cytotoxic7 Only preservative free portion140 preservative free NS61 puncture11,13 - auxiliary label62: methotrexate may be “IT” administered by the - label to include intrathecal route140 route in full (i.e., 50 mg/2mL147 INTRATHECAL (Hospira) injection) attached (RT)(PFL) to both syringe and no preservative140 outer ziplock bag62 Methotrexate 50 mg/2mL N/A 25 mg/mL140 24 h F141 syringe 14 d F87,141 - cytotoxic7 500 mg/20mL - high-dose (Hospira) regimen(e.g., 1-8 (RT)(PFL) g/m2 as a single preservative140 dose)144-146: use preservative-free methotrexate11 - do not use for IT injection 0.4–2 mg/mL140 4 h RT140 e.g., 100 mL*NS, D5W140 Mitomycin 5 mg SWI 0.5 mg/mL148 48 h F, RT13,148 syringe13 14 d F, 48 h RT13,148 - cytotoxic7 20 mg 5 mg: 10 mL (PFL)148 (Novopharm) 20 mg: 40 mL (RT)(PFL) no preservative148 shake well148 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 37/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 38. 0.02-0.04 mg/mL148 3 h RT: D5W 12 h RT: NS NS, D5W, sodium 24 h RT: sodium lactate148 lactate148 Mitomycin 5 mg SWI 0.5 mg/mL149 48 h F, RT13,149 syringe11 14 d F, 48 h RT11,21 - cytotoxic7 20 mg 5 mg: 10 mL (BMS) 20 mg: 40 mL (PFL)149 (RT)(PFL) no preservative149 shake well149 0.02–0.04 mg/mL 12 h RT: NS 3h: D5W NS, D5W, sodium 24 h: sodium lactate149 lactate149 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 38/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 39. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Mitoxantrone 20 mg/10 mL N/A 2 mg/mL150 discard unused 0.2-0.6 mg/mL150 NS: 24 h F, RT150 - cytotoxic7 25 mg/12.5 mL portion150 (Hospira) NS, D5W150 **(PFL)150 (RT)(PFL) no preservative150 > 50 mL*150 Mitoxantrone 20 mg/10 mL N/A 2 mg/mL151 discard unused NS, D5W151 24 h RT151 - cytotoxic7 (Novopharm) portion151 (RT)(PFL) > 50 mL*151 **(PFL)152 no preservative151 Mitoxantrone 20 mg/10 mL N/A 2 mg/mL153 discard unused NS, D5W2 24 h RT153 - cytotoxic7 (Pharmaceutical portion153 > 50 mL*153 Partners of Canada) (RT) no preservative153 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 39/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 40. Octreotide 50 mcg/mL; 100 N/A 50 mcg/mL discard unused sc syringe154 single use vials: use - noncytotoxic mcg/mL; 500 mcg/mL 100 mcg/mL portion154 within 4 h (Novopharm) 500 mcg/mL154 multidose vials: use (F)(PFL) within 14 d F74,154 no preservative multidose vials (5mL): 200 µg/mL (F)(PFL) 154 preservative 200 mcg/mL154 14 d F74,154 infusion: NS154 single use vials or multidose vials: 24 h RT154 Octreotide (Sandostatin) N/A 200 mcg/mL18 discard unused 50–200 mL NS18,11,156 24 h RT18 - noncytotoxic10 1000 mcg/5 mL portion155 (Novartis) (F)(PFL) SC infusion: adjust preservative18 volume to ensure infusion rate of 25 mcg/h18 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 40/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 41. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Octreotide (Sandostatin) N/A 50 mcg/mL discard unused 50-100 mL11,156 24 h RT18 - noncytotoxic10 50 mcg/1 mL 100 mcg/mL portion18 100 mcg/1 mL 500 mcg/mL18 NS18 500 mcg/1 mL (Novartis) SC infusion: adjust (F)(PFL) volume to ensure no preservative18 infusion rate of 25 mcg/h18 Octreotide (Sandostatin LAR) 2 mL supplied 10 mg: 5 mg/mL discard unused deep intragluteal use within 4 h of initial - noncytotoxic10 10 mg diluent 20 mg: 10 mg/mL portion18 administration only18 reconstitution18,13 - do NOT shake 20 mg 30 mg: 15 mg/mL18 30 mg gently run 2 mL (Novartis) down sides of the (F)(PFL) vial; do NOT preservative155 disturb for 2–5 min, then swirl moderately18 record time of reconstitution BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 41/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 42. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Oxaliplatin 50 mg/10 mL N/A 5 mg/mL157 discard unused 0.2-1.3 mg/mL158 0.2-1.3 mg/mL: - cytotoxic7 100 mg/20 mL portion157 14 d F, 48 h RT159,87,158 - do NOT use 200 mg/40 mL 1.3–2 mg/mL157,158 aluminum- (Sanofi-Aventis) 1.3-2 mg/mL: containing needle, (RT)(PFL) 250–500 mL D5W157 48 h F, 24 h RT157 syringe or no preservative157 tubing157 do NOT use NS or other chloride- containing solution157 do NOT use aluminum-containing needle and syringe157 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 42/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 43. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Oxaliplatin 50 mg SWI, D5W: 5 mg/mL160 24 h F160 500 mL D5W 24 h F, 6 h RT160 - cytotoxic7 100 mg 50 mg: 10 mL - do NOT use (Sigmacon) 100 mg: 20 mL do NOT use NS or aluminum- (RT) other chloride- containing needle, no preservative160 do NOT use NS or containing solutions syringe or tubing160 other chloride- (degrades)160 containing solution160 do NOT use aluminum-containing do NOT use needle and syringe160 aluminum- containing needle and syringe160 Paclitaxel 30 mg/5 mL N/A 6 mg/mL162 8 h RT162 0.3–1.2 mg/mL in NS, 0.3-1.2 mg/mL: - cytotoxic7 100 mg/16.7 mL D5W162 24 h RT162 - use non-PVC bag 300 mg/50 mL (e.g., 100–1000 mL)* and tubing with in- (Biolyse) 0.1 mg/mL: line filter162 (RT)161 44 h F, RT163 no preservative 0.1 mg/mL in NS163 0.012-0.09 mg/mL: 0.012-0.1 mg/mL164 16 h RT164 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 43/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 44. Paclitaxel 30 mg/5 mL N/A 6 mg/mL165 30 mg: 48 h 0.3–1.2 mg/mL in NS, 24 h RT165 - cytotoxic7 100 mg/16.7 mL RT13,165 D5W, D5-NS, D5 in - use non-PVC and 300 mg/50 mL 100 mg: 48 h Ringer’s165 tubing with in-line (BMS) RT13,165 filter165 (RT)(PFL) 300 mg: 24 h (e.g.,100–1000 mL)* no preservative165 RT165 0.1–1 mg/mL in NS, 48 h F, RT166 D5W166 Devices with spikes e.g., chemo dispensing pins, should not be used with paclitaxel vials165 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 44/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 45. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Paclitaxel, nab 100 mg paclitaxel and inject 20 mL NS 5 mg/mL167 8 h F, in empty 8 h RT167 - cytotoxic167 approximately 900 mg over > 1 min (a PFL167 sterile PVC or non- - do NOT filter167 human albumin chemo pin may be PVC infusion - non-PVC tubing is (Abraxis Oncology) used)168 bag167,168 NOT needed (RT)(PFL) - direct flow to - the use of an in- no preservative167 INSIDE vial wall line filter is not - stand solution for recommended168 > 5 min - gently swirl and/or invert vial slowly for > 2 min167 Pamidronate 30 mg/10 mL N/A 3 mg/mL discard unused 0.06–0.36 mg/mL NS, 24 h F followed by 24 h - noncytotoxic171 60 mg/10 mL 6 mg/mL portion169 D5W169 RT (total 48 h)169 90 mg/10 mL 9 mg/mL169 (Hospira) do NOT mix with **(PFL)169 (RT) calcium containing no preservative169 solution (e.g., Ringer’s)169 e.g., 250 mL NS170 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 45/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 46. Pamidronate 30 mg/10 mL N/A172 3 mg/mL discard unused NS or D5W172 24 h RT172 - noncytotoxic171 60mg/10 mL 6 mg/mL portion172,74 90 mg/10 mL 9 mg/mL172 do NOT mix with (Sandoz Canada) calcium containing RT solution (e.g., no preservative172 Ringer’s)172 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 46/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 47. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Panitumumab 100 mg/5 mL N/A 20 mg/mL173 discard unused ≤1000 mg: 100 mL 24 h F, 6 h RT173,174 - cytotoxic3 200 mg/10 mL portion173 NS173 - administer with 400 mg/20 mL 0.2 or 0.22 micron (Amgen) >1000mg: 150 mL low protein binding (F)(PFL) NS173 in-line filter173 do not shake - solution may no preservative173 1-10mg/mL173,174 contain particulates which do not affect product quality173 - do not administer if discoloured173 Pemetrexed 100 mg 100 mg: 4.2 mL 25 mg/mL175 24 h F, RT175 100 mL 24 h F, RT175 - cytotoxic7 500 mg preservative-free preservative-free (Eli Lilly) NS NS175 (RT) 500 mg: 20 mL do NOT mix with no preservative175 preservative-free calcium containing NS175 solution (e.g., Ringer’s)176 Porfimer 15 mg 6.6 mL D5W 2.5 mg/mL177 24 h F syringe177 use within 4 h of initial - noncytotoxic7 75 mg 31.8 mL D5W177 (PFL)177 reconstitution13,178 - avoid contact with (Axcan) skin and eyes; (RT)(PFL) record time of **(PFL)177 protect exposed no preservative177 reconstitution area from light177 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 47/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 48. Raltitrexed 2 mg 4 mL SWI179 0.5 mg/mL179 24 h F, RT179 50–250 mL NS, 24 h F, RT179 - cytotoxic7 (AstraZeneca) D5W179 (F, RT)(PFL) no preservative179 Raltitrexed 2 mg 4 mL SWI180 0.5 mg/mL180 24 h F, RT180 50–250 mL NS, 24 h F, RT180 - cytotoxic3 (Hospira) D5W180 (F, RT)(PFL) no preservative180 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 48/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 49. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Rituximab 100 mg/10 mL N/A 10 mg/mL181 discard unused 1–4 mg/mL in NS, 24 h F + additional 12 - noncytotoxic3 500 mg/50 mL portion181 D5W) 181 h RT181 (Roche) (F)(PFL) (e.g., 500 mg/250 mL, no preservative181 1000 mg/500 mL)* Streptozocin 1g 9.5mL NS, SWI, 100 mg/mL182 48 h F,182 24 h RT syringe182 48 h F, 24 h RT182 - cytotoxic7 (Pfizer) D5W182 (F)(PFL) no preservative182 50-500 mL*NS, D5W, 48 h F, 24 h RT182 SWI182 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 49/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 50. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Temozolomide 100 mg 41 mL SWI183 2.5 mg/mL183 14 h F, RT183 empty 250 mL PVC 14 h RT183 - cytotoxic{3 (Schering) bag183 (F) do not dilute183 do not shake183 no preservative183 Temsirolimus 30 mg/1.2 mL 1.8 mL supplied 10 mg/mL184,185 24 h RT184,185 250 mL NS184,185 Complete - cytotoxic3 (Wyeth) diluent184,185 (PFL)184 administration within 6 - use non-PVC bag (F)(PFL)184,185 h184,185 and non-PVC no preservative186 tubing with in-line filter184,185 Teniposide 15 mg/1.5 mL N/A 10 mg/mL18 discard unused 0.1, 0.2, 0.4, or 1 0.1, 0.2, 0.4mg/mL: 24 - cytotoxic7 (Bristol) portion18 mg/mL in NS or h RT18 - do NOT (RT) D5W18 refrigerate18 preservative18 1 mg/mL: complete - use non-PVC bag administration within and tubing18 4h of preparation18 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 50/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 51. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Thiotepa 15 mg 1.5 mL SWI187 10 mg/mL187 8 h F187 50 mL* NS187 use within 4 h of initial - cytotoxic7 (Bedford) reconstitution188,187 - do not use if (F)(PFL) filter through 0.22 **(PFL)187,189 precipitates or no preservative187 micron filter187 remains opaque187 record time of - do not use for IT reconstitution injection syringe: reconstituted use within 4 h of initial solution is hypotonic reconstitution188,187 and must be further **(PFL)187,189 diluted with NS prior to use187 (final concentration of 0.5-1 mg/ml is nearly isotonic)190 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 51/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 52. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Thiotepa IT injection: diluents containing 10 mg/mL187 8 h F187 qs to 6 mL with use within 4 h of initial - auxiliary label61 15 mg preservatives should preservative free reconstitution188,187 “IT” (Bedford) NOT be used for NS191 **(PFL)187,189 - label to include (F)(PFL) intrathecal route in full (i.e., no preservative187 administration INTRATHECAL injection) attached 1.5 mL SWI187 to both syringe and outer ziplock bag61 filter through 0.22 - cytotoxic7 micron filter187 - do not use if record time of precipitates or reconstitution remains opaque187 Thyrotropin alfa 1.1 mg 1.2 mL SWI192 0.9 mg/mL192 24 h F192 syringe192 24 h F192 - noncytotoxic (Genzyme) (F)(PFL) swirl contents192; do no preservative192 not shake BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 52/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 53. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Tocilizumab 80 mg/4 mL N/A 20 mg/mL193 6 h193, 21 100 mL NS 24h F193; - cytotoxic3 200mg/10 mL 6 h RT194 - to prevent 400 mg/20 mL dilute to 100 mL final foaming: slowly (Genentech) volume by add drug to (F)(PFL) withdrawing volume infusion bag and no preservative193 of NS from 100 mL gently invert bag to bag equal to volume mix193 of drug required for dose prior to adding drug193 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 53/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 54. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Topotecan 4 mg 4 mL SWI195 1 mg/mL195 24 h F, RT195 0.01–0.5 mg/mL197 24 h F, RT195 - cytotoxic7 (GSK) (RT)(PFL) 50 mL NS, D5W195 no preservative195,196 Topotecan 4 mg 4 mL SWI198 1 mg/mL198 24 h F, RT198 0.020 – 0.5 mg/mL198 24 h F, RT198 cytotoxic3 (GSK) (RT)(PFL) single use no preservative198 Trastuzumab 440 mg 20 mL supplied BWI 21 mg/mL199 14 d F13,199 250mL NS199 24 h F, RT199 - noncytotoxic3 (Roche) - do NOT shake199 (F) swirl vial gently; do NOT use dextrose preservative199 allow to stand containing solutions199 undisturbed for 5 min199 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 54/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 55. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Treosulfan 1g pre-heat SWI to 50 mg/mL200 48 h RT13,200 undiluted201 48 h RT13,200 - cytotoxic3 5g 30°C (not higher) - compatible with (medac) shake vial carefully dilute with NS or D5W polytetrafluoroethyl (RT) before adding the in empty infusion bag ene filters200 no preservative200 warmed SWI for final concentration - may require 1 g vial: 20 mL SWI, = 20 mg/mL200 vigorous shaking to while slightly reconstitute200 shaking vial and syringe; continue shaking the reconstituted solution for another 2 min{{10494}} 5 g vial: 100 mL SWI, while slightly shaking vial and syringe; continue shaking the reconstituted solution for another 2 min200 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 55/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 56. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Vinblastine 10 mg/10 mL N/A 1 mg/mL154 discard unused syringe11,154 4 h F, RT202,203 - cytotoxic7 (Hospira) portion154 - label with: (F)(PFL) WARNING: FOR no preservative154 INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES204,205 100–250 mL NS, 24 h F, RT202,203 D5W206 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 56/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 57. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Vincristine 2 mg/2 mL N/A 1 mg/mL207 8 h F, RT207 50 mL*NS, D5W207 24 h F, 6 h RT,207 - cytotoxic7 5 mg/5 mL - label with: (Hospira) **(PFL)207 WARNING: FOR (F)(PFL) INTRAVENOUS no preservative207 USE ONLY – FATAL IF GIVEN BY OTHER ROUTES204,205 Vincristine 1 mg/1 mL N/A 1 mg/mL208 14 d F, RT208 50 mL*NS, D5W208 72 h F, 24 h RT65 - cytotoxic7 2 mg/2 mL - label with: 5 mg/5 mL **(PFL)208 WARNING: FOR (Novopharm) INTRAVENOUS (F)(PFL) USE ONLY – preservative208 FATAL IF GIVEN BY OTHER ROUTES204,205 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 57/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 58. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Vinorelbine 10 mg/1 mL N/A 10 mg/mL209 discard unused syringe: 1.5 – 3.0 24 h F, RT209 - cytotoxic7 50 mg/5 mL portion209 mg/mL in NS or - label with: (GSK) D5W209 WARNING: FOR (F)(PFL) INTRAVENOUS no preservative209 USE ONLY – FATAL IF GIVEN BY OTHER ROUTES204,205 0.5 – 2.0 mg/mL209 24 h F, RT209 50 mL*NS, D5W, ½NS, D5½NS, Ringer’s, Ringer’s Lactate209 Vinorelbine 10 mg/1 mL N/A 10 mg/mL210 discard unused syringe: 1.5 – 3.0 24 h F, RT210 - cytotoxic7 50 mg/5 mL portion210 mg/mL in NS or - label with: (Hospira) D5W210 WARNING: FOR (F)(PFL) INTRAVENOUS no preservative210 USE ONLY – FATAL IF GIVEN BY OTHER ROUTES204,205 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 58/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 59. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) 0.5 – 2.0 mg/mL210 24 h F, RT210 50 mL* NS, D5W, ½NS, D5½NS, Ringer’s, Ringer’s Lactate210 Vinorelbine 10 mg/1 mL N/A211 10 mg/mL211 discard unused syringe: 1.5-3.0 24 h F, RT211 - cytotoxic3 50 mg/5mL portion211 mg/mL in D5W or - label with: (Pierre Fabre Pharma NS211 WARNING: FOR Canada) INTRAVENOUS (F)(PFL) USE ONLY – no preservative211 FATAL IF GIVEN BY OTHER ROUTES204,205 0.5-2.0 mg/mL211 24 h F, RT211 NS, D5W, ½NS, D5½NS, Ringer’s, Ringer’s Lactate211 BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 59/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 60. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 60/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 61. * Suggested volume based on usual dose range and any concentration range of stability data ** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting container and tubing during administration) will be indicated in the Under the Special Precautions/Notes column. Centres are not to change the content locally but should forward suggestions to the Cancer Drug Manual staff. Explanatory Notes Stability data assume products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification outlined in USP 797.21,212 Vial stability: Stability of solution after first puncture or reconstituted solution Storage temperature: If information states same stability with refrigerator and room temperature storage, then bold refrigerated as preferred (ie, to minimize growth of micro-organisms). Cytotoxic: hazardous (see Policy II-20 for more details). Discard unused portion: Unused portion from single use vials should be discarded at the end of the day. State “overfill known” if the manufacturer states overfill within acceptable limits is present. PFL = protect from light RT = room temperature F = refrigerated SWI = sterile water for injection NS = normal saline D5W = dextrose 5% BWI = bacteriostatic water for injection BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 61/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 62. References 1. Novartis Pharmaceuticals Canada Inc. PROLEUKIN® product monograph. Dorval, Quebec; 6 July 2006. 2. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 917-925. 3. National Institute for Occupational Safety and Health (NIOSH). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati, Ohio: NIOSH - Publications Dissemination; September 2004. p. 31-40. 4. Rui Paiva. Personal communication. Business Unit Director, Transplant and Oncology; 1 June 2009. 5. Bayer HealthCare Pharmaceuticals. MabCampath® Package Insert. Toronto, Ontario; 1 September 2007. 6. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004(18):484-490. 7. National Institute for Occupational Safety and Health (NIOSH). Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Healthcare Settings (Draft). Cincinnati, OH; 25 March 2004. 8. Berlex Canada Inc. Campath Drug Information. San Antonio, Texas; undated. 9. Schering AG. MABCAMPATH® Package Leaflet. Berlin, Germany; April 2002. 10. MedImmune Pharma B.V. Ethyol Package Insert. The Netherlands; 2003. 11. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005. 12. Erfa Canada Inc. AMSA PD® injection product monograph. Westmount, Quebec; 16 August 2005. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 62/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 63. 13. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006. 14. Tanya Leduc. Personal communication. Acting editor, BC Cancer Agency Cancer Drug Manual; 2 June 2008. 15. National Institute for Occupational Safety and Health (NIOSH). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati, Ohio: NIOSH - Publications Dissemination; 25 March 2004. p. 71-83. 16. Orphan Pharma International. Kidrolase Product Monograph. Limonest, France; 2005. 17. Robert Sarrazin B Pharm. Personal communication. Consultant, OPi Inc. February 2005. 18. Repchinsky C editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004. 19. OPi SAS. Kidrolase Product Monograph. Laval, Quebec; 2003. 20. Rhone-Poulenc Rorer. Kidrolase Package Insert. Montreal, Quebec; 2004. 21. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004. 22. Orphan Pharma International. Erwinase Product Monograph. Limonest, France; 2005. 23. Enzon Pharmaceuticals Inc. Oncaspar Product Monograph. Bridgewater, New Jersey; 2003. 24. BC Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer Agency; 1 September 2006. 25. Celgene. VIDAZA® product monograph. Oakville, Ontario; 22 October 2009. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 63/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 64. 26. Carol Repchinsky. ImmuCyst monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario; 2005. 27. Organon Canada Ltd. OncoTICE® Product Monograph. Scarborough, Ontario; 24 October 2001. 28. Cephalon. TREANDA® prescribing information. Frazer, PA; October 2009. 29. Roche. Bevacizumab for injection, Summary product information. Mississauga, Ontario; 2005. 30. Hoffmann-La Roche Limited. Ro 4876647 Avastin Investigator's Brochure. Mississauga, Ontario; 14th edition, November 2006. 31. Carol Repchinsky. Blenoxane monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario; 2005. 32. Catherine Dehaut M.Sc. Personal communication. Medical Information Associate, Bristol Laboratories of Canada; February 2008. 33. Faulding (Canada) Inc. Bleomycin Product Monograph. Montreal, Quebec; 3 June 2002. 34. Sheila Ahmed. Personal communication Bleomycin. Regulatory Affairs Associate, Bleomycin, Mayne Pharma Canada. Ref JUN-128-2004; July 2, 2004. 35. Robert Caunce. Personal communication. Quality System Manager, Hospira Australia; 12 March 2008. 36. Millenium Pharmaceuticals Inc. Velcade product monograph. Cambridge, Massachusetts; May 2003. 37. Walker S, Milliken D, Law S. Stability of bortezomib vials reconstituted with 0.9% sodium chloride at 4ºC and room temperature (23ºC). Canadian Journal of Hospital Pharmacy 2006;59 (Suppl 1):62. 38. Janssen-Ortho Inc. VELCADE® product monograph. Toronto, Ontario; 18 April 2006. 39. Orphan Medical Inc. Busulfex Package Insert. Flamborough, Ontario; August 1999. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 64/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 65. 40. Mayne Pharma (Canada) Inc. Carboplatin Package Insert. Montreal, QC; Undated. 41. Nancy Grioriadis. Personal communication. Regulatory Affairs Associate, Mayne Pharma (Canada) Inc. 2 October 2006. 42. Nancy Griogoriadis. Personal communication. Regulatory Affairs Associate, Mayne Pharma (Canada) Inc. 2 October 2006. 43. Novopharm Limited. Carboplatin Package Insert. Toronto, Canada; Undated. 44. Manjinder S Kang. Personal communication. Regulatory Affairs Drug Information Pharmacist, Novopharm Canada. 14 March 2005. 45. Repchinsky C. Paraplatin-AQ, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004. 46. Bristol Laboratories of Canada. BiCNU Package Insert. Montreal, Canada; 2002. 47. ImClone Systems Incorporated and Bristol-Myers Squibb Company. ERBITUX® product monograph. Branchburg, NJ, USA; March 2009. 48. Mayne Pharma (Canada) Inc. Cisplatin Package Insert. Montreal, QC; Undated. 49. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003. 50. Repchinsky C. Cisplatin CPhA monograph, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004. 51. Janssen-Ortho Inc. LEUSTATIN® Product Monograph. Toronto, Ontario; 31 July 2006. 52. BC Cancer Agency Lymphoma Tumour Group. (LYCDA) BCCA Protocol Summary for Treatment of Hairy Cell Leukemia with Cladribine. Vancouver, British Columbia: BC Cancer Agency; 1 February 2007. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 65/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 66. 53. Myrna O'Brodovich. Personal communication. Senior Medical Information Associate Ortho Biotech; 2 April 2008. 54. de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract 2007;13(1):27-31. 55. Oryx Pharmaceuticals Inc. Clasteon Product Monograph. Mississauga, Ontario; 25 November 2004. 56. Baxter Corporation. Procytox Package Insert. Toronto, Ontario; 2004. 57. Paul Agro. Personal communication. Medical Information, cyclophosphamide, Baxter. 12 July, 2006. 58. Novartis Pharmaceuticals Canada Inc. NEORAL® & SANDIMMUNE® I.V. product monograph. Dorval, Quebec; 30 September 2008. 59. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 418-420. 60. Mayne Pharma (Canada) Inc. Cytarabine Injection Product Monograph. Montreal, Quebec; 25 July 2003. 61. BC Cancer Agency Miscellaneous Origin Tumour Group. BCCA protocol summary for solid tumours using intrathecal methotrexate and/or thiptepa and/or cytarabine (MOIT). Vancouver, British Columbia: BC Cancer Agency; 1 July 2005. 62. BC Cancer Agency. Systemic Therapy Policy III-50: Administration of Cytotoxic Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; 31 October 2002. 63. Pfizer Canada Inc. CYTOSAR® Sterile Powder Product Monograph. Kirkland, Quebec; 17 March 2004. 64. BPharm Yamina Chikhaoui PhD. Personal communication. Medical Information, Pfizer Canada. February 2005. 65. Novopharm Limited. Vincristine product monograph. Scarbough, Canada; 1999. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 66/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 67. 66. Abraxis Pharmaceutical Products. Dacarbazine product information package. Schaumburh, IL; December 2006. 67. Trissel L. Handbook on injectable drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 428-431. 68. Mayne Pharma (Canada) Inc. DACARBAZINE FOR INJECTION product monograph. Montreal, Quebec; 25 July 2003. 69. John Korontzis. Personal communication. Regulatory Affairs Associate, Dacarbazine, Mayne Pharma Canada; #FEB-14-2005 (february 8, 2005). 70. Jane Stachura. Personal communication. Ovation Pharmaceuticals Inc; 12 January 2009. 71. Ovation Pharmaceuticals Inc. COSMEGEN® product monograph. Deerfield, Illinois; 19 August 2008. 72. Patricia Hamelin-Dandridge RN. Personal communication. Medical Information Research Associate, Ovation Pharmaceuticals; 24 October, 2008. 73. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 431. 74. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007. 75. Erfa Canada Inc. Daunorubicin injection product monograph. Westmount, Quebec; 6 December 2002. 76. Erfa Canada Inc. Material Safety Data Sheet. Montreal, Quebec; 3 October 2007. 77. Henri Knafo MD. Personal communication. Medical Director, Erfa Canada Inc; 14 July 2008. 78. Henri Knafo MD. Personal communication. Medical director, Erfa Canada Inc; 09 July 2008. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 67/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 68. 79. Novopharm Limited. Daunorubicin Package Insert. Toronto, Canada; Undated. 80. Pharmacia & Upjohn Inc. Zinecard Package Insert. Mississauga, Ontario; 2004. 81. Pharmacia & Upjohn Company. Zinecard: US Prescribing Information. Kalamazoo, Michigan; September 2003. 82. Emmanuelle Laflamme B.Pharm. Personal communication. Medical Information Officer, Dexrazoxane, Pfizer. February 2005. 83. Aventis Pharma Inc. Taxotere Package Insert. Laval (Quebec) Canada; 2004. 84. Maureen Coughlin BSc Pharm. Personal communication. SOLUTIONS in Health; 28 September 2009. 85. Walker S, Charbonneau F, Law S. Stability of docetaxel in normal saline at room temperature (abstract). Can J Hosp Pharm 2003;56 (Suppl PPC):S51. 86. Walker S, Charbonneau F, Law S. Stability of docetaxel in normal saline at room temperature. Can J Hosp Pharm (in press). 87. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2003. 88. Mayne Pharma (Canada) Inc. Doxorubicin Package Insert. Montreal, QC; Undated. 89. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, Quebec; 2002. 90. John Korontzis. Personal communication. Regulatory Affairs Associate, Doxorubicin, Mayne Pharma Canada; February 2005. 91. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 8 November 1996. 92. Pfizer Canada Inc. Adriamycin injection product monograph. Kirkland, Quebec; 28 August 2007. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 68/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 69. 93. Schering Canada Inc. Caelyx Package Insert. Pointe-Claire, Quebec; September 2001. 94. Pharmacia Canada Inc. Pharmorubicin PFS Package Insert. Mississauga, Ontario; May 2003. 95. Bristol Laboratories of Canada. Vepesid Package Insert. Montreal, Canada; March 2000. 96. Nicole Hojm and Kinda Karra. Personal communication. Medical Information, etoposide, Bristol-Myers Squibb. February 2005. 97. The United States Pharmacopeial Convention, Inc. General Chapter 797 proposed revisions. ; 2006. 98. The United States Pharmacopeial Convention, Inc. General Chapter 51: Antimicrobial effectiveness testing. USP 28-NF 23. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004. 99. Novopharm Limited. Etoposide Product Monograph. Toronto, Ontario; 2000. 100. Lepage R, Walker S, Godin J. Stability and compatibility of etoposide in normal saline. Canadian Journal of Hospital Pharmacy 2000;53(5):338-345. 101. Angie Chan. Personal communication. Drug Information Pharmacist, Novopharm. 29 September 2006. 102. Berlex Canada Inc. Fludara Package Insert. Lachine, Quebec; December 1998. 103. Trissel's™2 Clinical Pharmaceutics Database (Parenteral Compatibility) [database on the internet]. Fludarabine. Thomson MICROMEDEX®, Available at: http://www.micromedex.com/. Accessed 14 September, 2007. 104. Novopharm Limited. Fludarabine product information package. Toronto, Ontario; 21 June 2007. 105. Mayne Pharma (Canada) Inc. Fluorouracil Package Insert. Montreal, Quebec; Undated. 106. John Korontzis. Personal communication. Regulatory Affairs Associate, Fluorouracil, Mayne Pharma Canada; reference # FEB-43-2005.February 16, 2005. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 69/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 70. 107. Stiles ML, Allen Jr LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy 1989;46(10):2036-2040. 108. Eli Lilly Canada Inc. Gemzar Package Insert. Toronto, Ontario; 16 January 2002. 109. Marilyn Bain BSc N. Personal communication. Sr Therapeutic Area Specialist Medical Information, Gemzar. September 2004. 110. Hospira Healthcare Corporation. Gemcitabine for injection, USP product monograph. Montreal, Quebec; 3 November 2008. 111. Rose Toussaint. Personal communication. Clinical Specialist, Hospira Canada Healthcare Corporation; 26 May2009. 112. Hospira Canada Clinical Support Team. Personal communication. Hospira Healthcare Corporation; 13 March 2009. 113. B.C. Cancer Agency - Pharmacy. Pharmacy Provincial Policy II-30: Guiding principles for chemotherapy preparation chart. Vancouver, British Columbia: BC Cancer Agency; 24 March 2004. 114. Novopharm Limited. Gemcitabine product monograph. Toronto, Ontario; 08 February 2008. 115. Sandoz Standard. Gemcitabine for injection product monograph. Boucherville, Quebec; 13 November 2007.2007. 116. Amelie Fontaine B.Sc (N). Personal communication. Drug Information Specialist, Sandoz (vial); 9 April 2009. 117. Stephane Jean B. Pharm. Personal communication. Sandoz Canada Drug Information; 7 May 2008. 118. Stephane Jean. Personal communication. Drug Information Specialist; 25 September 2009. 119. Amelie Fontaine B.Sc (N). Personal communication. Drug Information Specialist, Sandoz (infusion); 9 April 2009. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 70/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 71. 120. Pharmacia & Upjohn Inc. Idamycin Package Insert. Mississauga, Ontario; July 1997. 121. Natalie Groves BScN. Personal communication. Medical Information Specialist, Pfizer Canada Inc. 7 March 2007. 122. Baxter Corporation. Ifex Package Insert. Toronto, Ontario; Undated. 123. Schering Canada Inc. Intron A Package Insert. Pointe-Claire, Quebec; January 2003. 124. Julie Lacasse BScN RN. Personal communication. Associate Medical Information, Schering. February 2005. 125. Schering Canada. Intron A Product Monograph. Pointe Claire Quebec; December 2004. 126. Edward Kavalec. Intron A (interferon alpha-2b). Schering Canada - Medical Services. 2006. 127. Mayne Pharma (Canada) Inc. Irinotecan Package Insert. Montreal, Quebec; 28 April 2005. 128. Beryl Chan. Personal communication. Mayne Pharma (Canada) Inc. Scientific Affairs Manager, Irinotecan. 2 February 2006. 129. Walker S, Iazzetta J, Law S. Irinotecan stability in vials following puncture when stored at 23c or 4c. Can J Hosp Pharm 2006;59 (Suppl 2):36. 130. Pharmacia Canada Inc. Camptosar Package Insert. Mississauga, Ontario; May 2002. 131. Sandoz Canada Inc. Irinotecan injection package insert. Boucherville, Quebec; April 2008. 132. Bristol-Myers Squibb. IXEMPRA® product monograph. Princeton, New Jersey; 01 October 2007. 133. Faulding (Canada) Inc. Leucovorin Package Insert. Montreal, QC; Undated. 134. John Korontzis. Personal communication. Regulatory Affairs Associate, Leucovorin Calcium, Mayne Pharma Canada; February 2005. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 71/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 72. 135. Novopharm Limited. Leucovorin Calcium injection product information package. Toronto, Ontario; undated. 136. Ovation Pharmaceuticals Inc. MUSTARGEN® Package Insert. Deerfield, Illinois; October 2005. 137. BC Cancer Agency. Systemic Therapy Policy III-20: Extravasation of Chemotherapy, Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer Agency; 1 July 2006. 138. GlaxoSmithKline Inc. Alkeran Package Insert. Mississauga, Ontario; Montreal, Quebec; 2004. 139. Pharmaceutical Partners of Canada Inc. Mesna Package Insert. Richmond Hill, Ontario; November 2001. 140. Mayne Pharma Canada. Methotrexate Product Monograph. Montreal, Quebec; December 2003. 141. John Korontzis. Personal communication. Regulatory Affairs Associate, Methotrexate, Mayne Pharma Canada; February 2005. 142. John Korontzis. Personal communication. Regulatory Affairs Associate, Fluorouracil, Methotrexate, Vincristine, Mayne Pharma Canada; 14 March 2005. 143. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for treatment of primary intracerebral lymphoma with high dose methotrexate (LYHDMTXP). Vancouver, British Columbia: BC Cancer Agency; 1 June 2004. 144. BC Cancer Agency Lymphoma Tumour Group. BCCA protocol summary for treatment of leptomeningeal lymphoma or recurrent intracerebral lymphoma with high dose methotrexate (LYHDMTXR). Vancouver, British Columbia: BC Cancer Agency; 1 June 2004. 145. BC Cancer Agency Miscellaneous Origin Tumour Group. BCCA protocol summary for treatment of meningeal disease (miscellaneous tumour origins) using high dose methotrexate with leucovorin rescue (UMOHDMTX). Vancouver, British Columbia: BC Cancer Agency; 21 September 1999. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 72/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 73. 146. BC Cancer Agency Sarcoma Tumour Group. BCCA protocol summary for treatment of osteosarcoma using high dose methotrexate with leucovorin rescue (OSHDMTX). Vancouver, British Columbia: BC Cancer Agency; 1 August 2000. 147. BC Cancer Agency. Pharmacy Policy Number III-50-02: Methotrexate Intrathecal Injection. Vancouver, British Columbia: BC Cancer Agency; 27 January 2006. 148. Novopharm Limited. Mitomycin for Injection Product Monograph. Scarborough, Ontario; 23 December 1996. 149. Bristol Laboratories of Canada. Mutamycin Package Insert. Montreal, Canada; 2000. 150. Hospira Healthcare Corporation. Mitoxantrone Injection, USP Product Monograph. Saint-Laurent, Quebec; 13 June 2007. 151. Novopharm Limited. Mitoxantrone Injection Product Monograph. Toronto, Ontario; 19 May 2005. 152. Angie Chan. Personal communication. Drug Information Pharmacist, Novopharm; 7 Mar 2008. 153. Pharmaceutical Partners of Canada. Mitoxantrone Injection, USP Package Insert. Richmond Hill, Ontario; February 2007. 154. Novopharm Limited. Octrotide Injection Product Monograph. Scarborough, Ontario; 15 March 2007. 155. Repchinsky C. Sandostatin LAR monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005. p. 1912-1916. 156. Vancouver Hospital and Health Sciences Centre Pharmacy Department. Octreotide. Parenteral drug therapy manual. Vancouver, BC; February 2002. 157. sanofi-aventis Canada Inc. ELOXATIN® product monograph. Laval, Quebec; 13 January 2009. 158. Eiden C, Philibert L, Bekhtari K, et al. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health Syst Pharm 2009;66. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 73/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 74. 159. Andre P, Cisternino S, Roy A-, et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. American Journal of Health-System Pharmacy 2007;64(18):1950-1954. 160. Sigmacon Lifesciences. Oxaliplatin for injection. North York, Ontario; January 2006. 161. Claude Mercure. Personal communication. Production Manager Biolyse Pharma Corporation; 21 December 2009. 162. Biolyse Pharma. Paclitaxel Package Insert. Ontario, Canada; November 2002. 163. Mercure C. Stability of 0.1 mg/mL of paclitaxel for injection in sodium chloride (0.9%) solution. St Catharines, Ontario: Biolyse Pharma; 2 February 2007. 164. Zeng Z, Lazakovitch E. Study IR 120: Physical and Chemical Stability Study of Paclitaxel for Injection in 0.9 % Sodium Chloride in concentration range 0.012-0.12 mg/mL. Biolyse Pharma 10 March 2010. 165. Bristol-Myers Squibb Canada. Taxol Package Insert. Montreal, Quebec; September 2002. 166. Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm 1994;51(24):3058-60. 167. Abraxis Oncology. ABRAXANE® Product Monograph. Richmond Hill, Ontario; 26 June 2006. 168. Abraxis BioScience. Reconstitution of ABRAXANE®. Richmond Hill, ON; May 2008. 169. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002. 170. BC Cancer Agency Breast Tumour Group. BCCA protocol summary for treatment of acute bone pain secondary to breast cancer metastases using pamidronate or IV clodronate (BRAVPAM). Vancouver, British Columbia: BC Cancer Agency; 1 May 2001. 171. Novartis Pharmaceuticals Corporation. Aredia Product Monograph. East Hanover, New Jersey; 2003. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 74/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 75. 172. Sandoz Canada Inc. Pamidronate injection product monograph. Boucherville, Quebec; 28 February 2006. 173. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 5 March 2009. 174. Diane Lord. Personal communication. Amgen Canada Inc Medical Information Department; 19 June 2009. 175. Eli Lilly Canada. Pemetrexed product information. Toronto, Ontario; 2008. 176. Eli Lilly Canada Inc. ALIMTA Product Monograph. Toronto, Ontario; 21 May 2004. 177. Axcan Pharma Inc. Photofrin Package Insert. Mont-Saint-Hilaire, Quebec; 2004. 178. Marie-Helene Doyon B.Pharm. M.Sc. Personal communication. Medical Information Specialist, Porfimer, Axcan Pharma. 3 March 2005. 179. AstraZeneca. Tomudex Package Insert. Mississauga, Ontario; November 2001. 180. Hospira Healthcare Corporation. TOMUDEX® product monograph. Saint-Laurent, Quebec; 23 April 2008. 181. Hoffmann-La Roche Limited. Rituxan Package Insert. Mississauga, Ontario; December 2002. 182. Pharmacia Canada Inc. Zanosar Package Insert. Mississauga, Ontario; March 2003. 183. Schering-Plough Canada. TEMODAL® product monograph. Kirkland, Quebec; 5 January 2009. 184. Wyeth Canada. TORISEL® product monograph. Montreal, Canada; 16 October 2008. 185. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 1226-1228. 186. Anna Sivojelezova M.Sc. Personal communication. Medical Information Associate, Wyeth. 6 January 2010. 187. Bedford Laboratories™. Thiotepa for Injection USP Package Insert. Bedford, Ohio; April 2001. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 75/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 76. 188. Solimando D.A. Updates of melphalan and thiotepa. Hosp Pharm 1997;32(8):1082-1088. 189. Christina Hsu Pharm. D. Personal communication. Bedford Laboratories Professional Services Department; 29 August 2008. 190. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2005. p. 1395-1403. 191. BC Cancer Agency Miscellaneous Origin Tumour Group. (MOIT) BCCA Protocol Summary for Soild Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer Agency; 1 July 2005. 192. Genzyme Canada. Thyrogen Product Monograph. Mississauga, Ontario; 2004. 193. Genentech Inc. ACTEMRA® product information. South San Francisco, California; January 2010. 194. F. Hoffmann-La Roche Ltd. Provision of tocilizumab for a patient with multicentric Castleman's Disease: guidelines for compassionate use. May 2010. 195. GlaxoSmithKline. Hycamtin Package Insert. Mississauga, Ontario; Montreal, Quebec; 2001. 196. Victoria Vertesi. Personal communication. Oncology Marketing Manager GlaxoSmithKline; 30 October 2008. 197. Kramer I, Thiesen J. Stability of topotecan infusion solutions in polyvinylchloride bags and elastometric portable infusion devices. Journal of Oncology Pharmacy Practice 1999;5(2):75-82. 198. Sandoz Canada Inc. Topotecan product monograph. Boucherville, Quebec; 24 September 2009. 199. Hoffmann-La Roche Limited. Herceptin Package Insert. Mississauga, Ontario; October 2002. 200. medac UK. TREOSULFAN injection® product monograph. Hamburg, Germany; 24 June 2008. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 76/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 77. 201. Henrik Fenger. Personal communication. Management Assiciate, International Division medac; 03 March 2010. 202. Jan Barrow. Personal communication. Supervisor, Hospira Canada Clinical Support. Saint-Laurent, Quebec; 03 December 2007. 203. Tanya Leduc. Personal communication. Acting editor, BC Cancer Agency Cancer Drug Manual; 18 Dec 2007. 204. World Health Organization. Information Exchange System: Alert No. 115 (QSM/MC/IEA.115). Geneva, Switzerland: World Health Organization; 18 July 2007. 205. BCCA Provincial Systemic Therapy Program. Labeling of vinca alkaloid syringes. Policy # V-40. Vancouver, British Columbia: BC Cancer Agency; 27 May 1999. 206. Repchinsky C. Vinblastine CPhA monograph, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004. 207. Mayne Pharma (Canada) Inc. Vincristine Package Insert. Montreal, QC; Undated. 208. Novopharm Limited. Vincristine Package Insert. Toronto, Canada; Undated. 209. GlaxoSmithKline Inc. Navelbine Package Insert. Mississauga, Ontario; Montreal, Quebec; Undated. 210. Mayne Pharma (Canada) Inc. Vinorelbine Product Monograph. Montreal, QC; Undated. 211. Pierre Fabre Pharma Canada Inc. Vinorelbine injection package insert. St Bruno de Montarville, Quebec; undated. 212. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5. BC Cancer Agency Chemotherapy Preparation and Stability Chart© version 2.00 77/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010


Comments

Copyright © 2025 UPDOCS Inc.